System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 42590101 DOI: 10.3390/jcm15155997

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

J Clin Med 15(15)

Authors: Mustafa Murat Mıdık, Gökhan Şahin, Bekir Mert Durukan, Fatih Kuş, Kübra Haşimoğlu Gürün, Sinan Ünal, Cem Mirili, Canan Karan, Engin Hendem, Teoman Şakalar, Miray Aydoğan, Bahadır Köylü, Nadiye Sever, Bahattin Engin Kaya, Tülay Kuş, Canberk Şencan, Atike Pınar Erdoğan, Hatime Arzu Yaşar, Hilal Karakaş, Oğuzhan Yıldız, Bahiddin Yılmaz, Murat Alan, Bülent Çetin, Nedim Turan, Melek Karakurt Eryılmaz, Mehmet Artaç, İlkay Tuğba Ünek, Fatih Selçukbiricik, Mehmet Ali Şendur, Hasan Çağrı Yıldırım, Şuayib Yalçın

Affiliations

  • Department of Medical Oncology, Ege University Medical Faculty, 35100 Izmir, Turkey.
  • Department of Medical Oncology, Hacettepe University, 06800 Ankara, Turkey.
  • Department of Medical Oncology, Ankara Sanatorium Hospital, 06290 Ankara, Turkey.
  • Department of Medical Oncology, Ondokuz Mayıs University, 55270 Samsun, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Atatürk Training and Research Hospital, Izmir Katip Çelebi University, 35620 Izmir, Turkey.
  • Department of Medical Oncology, Adana Middle East Hospital, 01140 Adana, Turkey.
  • Department of Medical Oncology, Denizli Tekden Hospital, 20010 Denizli, Turkey.
  • Department of Medical Oncology, Mengücek Gazi Training and Research Hospital, Binali Yıldırım University, 24002 Erzincan, Turkey.
  • Department of Medical Oncology, Kahramanmaraş Necip Fazıl City Hospital, 46050 Kahramanmaraş, Turkey.
  • Department of Medical Oncology, Kartal Dr. Lütfi Kırdar City Hospital, 34865 Istanbul, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Koç University, 34450 Istanbul, Turkey.
  • Department of Medical Oncology, Haydarpaşa Sample Training and Research Hospital, 34668 Istanbul, Turkey.
  • Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, 42090 Konya, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Gaziantep University, 27410 Gaziantep, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Dokuz Eylül University, 35220 Izmir, Turkey.
  • Department of Medical Oncology, Hafsa Sultan Hospital Medical Oncology, Celal Bayar University, 45140 Manisa, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Ankara University, 06070 Ankara, Turkey.
  • Department of Medical Oncology, Ankara Bilkent City Hospital, 06800 Ankara, Turkey.

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Although the STRIDE regimen (durvalumab plus tremelimumab) has demonstrated an overall survival benefit in clinical trials, real-world evidence remains limited, particularly in Turkish clinical practice. This study aimed to evaluate the effectiveness and safety of first-line STRIDE therapy in patients with unresectable HCC treated in routine clinical practice. Methods: We conducted a retrospective multicenter study including patients with unresectable HCC who received first-line durvalumab plus tremelimumab through the Turkish national Early Access Program across 18 oncology centers. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and exploratory Cox regression analyses were performed to evaluate baseline prognostic factors. Results: Thirty-two patients were included. The median PFS was 7.25 months (95% CI, 3.68-22.29), and the median OS was 11.43 months (95% CI, 4.50-not reached). The underlying liver disease etiology was non-viral in 53.1% of patients, hepatitis B virus in 40.6%, and hepatitis C virus in 6.3%. Grade ≥ 3 treatment-related adverse events occurred in fewer than 10% of patients. Conclusions: In this multicenter real-world cohort, first-line durvalumab plus tremelimumab appeared to be a feasible treatment option and was generally well tolerated in patients with unresectable HCC. However, given the retrospective design, small sample size, and absence of a control group, these findings should be interpreted cautiously and require confirmation in larger prospective comparative studies.

MeSH

Carcinoma, Hepatocellular, Safety, Immunotherapy, Viruses, Therapeutics, Hepatitis